Last reviewed · How we verify
Matrix-M Adjuvant
At a glance
| Generic name | Matrix-M Adjuvant |
|---|---|
| Sponsor | Novavax |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) (PHASE1)
- Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant (PHASE1, PHASE2)
- Safety and Immunogenicity of NVX-CoV2705 (PHASE3)
- Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults (PHASE1)
- Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine (EARLY_PHASE1)
- COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
- Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matrix-M Adjuvant CI brief — competitive landscape report
- Matrix-M Adjuvant updates RSS · CI watch RSS
- Novavax portfolio CI